Increases the hydration levels in the skin and moisturizes it
72 hafta sren bir deneyde Wegovy kullananlarn, vcut arlnn yzde 14'n, Zepbound kullananlarn ise yzde 20'sini kaybettii gzlemlendi
Penyakit Hati Berlemak Terkait Disfungsi Metabolik (MASLD): Retatrutide dapat mengurangi kandungan lemak hati hingga 86%, dan lebih dari 85% pasien mencapai regresi steatosis hati
Genetic variants in GLP1R (e.g., rs6923761) and GIPR pathways can influence receptor sensitivity and medication response
Discontinuation and weight regain How often people stop the medication TRIUMPH-4 (n=445, 68 weeks, obesity with knee osteoarthritis): 18.2% on 12 mg, 12.2% on 9 mg, 4% on placebo 2 TRANSCEND-T2D-1 (n=537, 40 weeks, type 2 diabetes): 5.1% on 12 mg, 4.5% on 9 mg, 0% on placebo 3 Phase 2 (n=338, 48 weeks): 6 to 16% across doses, 1% on placebo 1 For comparison, Wegovys STEP-1 trial reported a discontinuation rate of around 7% due to side effects, and Mounjaros SURMOUNT-1 reported a similar rate
Innovation & R&D Support Indian pharmaceutical companies are not just manufacturers they are innovation partners